(lp0
S"Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class ... PR Newswire  - Mar 27, 2017 SAN FRANCISCO, March 27, 2017 /PRNewswire/ -- Nektar Therapeutics  today announced that it has begun dosing in a Phase 1 clinical study evaluating NKTR-358, the company's new biologic therapy, which is being developed to treat a&nbsp;...Just the Facts on Nektar Therapeutics  - StockNewsJournalFirms &amp; Funds Favorite: Nektar Therapeutics  - Midway Monitor"
p1
aS"Nektar Therapeutics' stock jumps after positive results of its pain treatment drug MarketWatch - Mar 20, 2017 Shares of Nektar Therapeutics NKTR, +4.28% soared 18% toward a six-month high in premarket trade Monday, after reporting positive results of a late-stage trial of its opioid analgesic.Why Nektar Therapeutics Inc. Is Rising Today - Motley FoolNektar Therapeutics  Has Surged To Nearly A 6-Month High On Study Results - Nasdaq"
p2
aS"Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results PR Newswire  - Mar 1, 2017 SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Nektar Therapeutics  today reported its financial results for the fourth quarter and year ended December 31, 2016.Nektar Therapeutics  Loss Wider than Expected in Q4 - Yahoo FinanceHere's What's Behind Nektar Therapeutics' 20% Move Higher - Motley Fool"
p3
aS'Nektar Therapeutics  Says NKTR-181 Met Primary, Secondary Endpoints in ... StreetInsider.com - Mar 20, 2017 Nektar Therapeutics  today announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic.'
p4
aS"Nektar Therapeutics: Touches near 11-year high Times of India - Mar 20, 2017 ... ** Drugmaker's shares up as much as 35 pct at near 11-year high of $20.91. ** Stock second-top percentage gainer on Nasdaq."
p5
aS"Can this company's pain-fighting drug smash America's opioid crisis? San Francisco Business Times - Mar 20, 2017 Facing skepticism, the company says its drug enters the brain slowly, so pain-drug addicts don't get the euphoric rush they seek, but patients get effective pain relief."
p6
aS'All You Need To Know About Nektar Therapeutics  Revealed Perfectly In ... NY Stock News - 20 hours ago The technicals for Nektar Therapeutics  have taken shape, and with them a comprehensive picture has emerged. This is the current state of play as presented by the current technical setup.'
p7
aS'An intrinsic value calculation for Nektar Therapeutics  shows investors ... Simply Wall St - Mar 21, 2017 I am going to run you through how I calculated the intrinsic value of Nektar Therapeutics  by taking the expected future cash flows and discounted them to the value today.'
p8
aS'Wall Street Cheers These Two Rising Stocks: Esperion Therapeutics Inc (ESPR ... Smarter Analyst - Mar 20, 2017 Esperion Therapeutics Inc  and Nektar Therapeutics  are skyrocketing with a fury today on back of major clinical strides forward that have investors today eagerly watching these needle-movers ascend up through the&nbsp;...After-hours buzz: ESPR, NKTR, MMSI &amp; more - CNBC12 Biggest Mid-Day Gainers For Monday - Benzinga'
p9
aS"Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics ... PR Newswire  - Mar 13, 2017 Pre-market, Stock-Callers.com navigates the Biotechnology space with focus on Nektar Therapeutics , Seattle Genetics Inc. , Dynavax Technologies Corp.What are Analyst's Indicators for Nektar Therapeutics , PDC Energy, Inc ... - The USA CommerceNektar Therapeutics  Shares Bought by Comerica Bank - BNB Daily "
p10
a.